登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688710 证券简称：益诺思 公告编号：2025-041 上海益诺思生物技术股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025年11月20日（星期四） 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2025年第三季度的经营成果及财务指标的具体情况 与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 董事、总裁：常艳女士 财务总监：高晓红女士 董事会秘书：李燕女士 独立董事：范国钦先生 （如有特殊情况，参会人员可能进行调整） 会议召开方式：上证路演中心网络互动 会议问题征集：投资者可于2025年11月19日(星期三)16:00前登录上证路演中心网站首页点击"提问 ...

Core Viewpoint - Pfizer is seeking to sell its remaining stake in its COVID-19 vaccine partner BioNTech, which is expected to generate up to approximately $508 million in proceeds for Pfizer [1] Group 1 - BioNTech's stock price dropped over 6% to $104.7 following the news of Pfizer's planned stake sale [1] - BioNTech stated that its collaboration with Pfizer remains unchanged and refrained from commenting on Pfizer's capital market activities [1]

Core Viewpoint - BioNTech confirms that its collaboration with Pfizer remains unchanged despite reports of Pfizer seeking to sell its stake in BioNTech [1] Group 1 - BioNTech's spokesperson stated that the company will continue to maintain a close and strong partnership with Pfizer [1] - The company will not comment on any capital market activities undertaken by Pfizer [1]

Group 1 - The core point of the article highlights that Beijing Bohui Innovation Biotechnology Group Co., Ltd. has achieved a significant trading volume of 1.011 billion RMB, marking the highest level since January 17, 2022 [2] - The latest stock price of the company has increased by 18.33%, with a turnover rate of 16.05% [2] - The previous trading day recorded a total trading volume of 458 million RMB for the stock [2] Group 2 - Beijing Bohui Innovation Biotechnology Group was established on July 12, 2001, with a registered capital of 8.16900495 billion RMB [2]

Core Insights - The total import and export trade volume of Youxian County reached 324 million yuan from January to September, with an impressive growth rate of 85.14%, ranking first in the city [1] - Specialized and innovative enterprises are the main contributors to Youxian's foreign trade success, supported by the local tax authority's focus on compliance and development [1][4] Group 1: Trade Performance - Youxian County's export business has shown significant growth, with specialized and innovative enterprises leading the charge [1] - Hunan Yitian Agricultural Machinery Co., Ltd. completed its first foreign trade order, marking a breakthrough in the agricultural machinery sector [2] Group 2: Compliance and Risk Management - Yitian's success is attributed to its commitment to compliance, which has helped mitigate risks associated with international market entry [4] - The local tax authority has conducted multiple training sessions and on-site visits to assist enterprises in risk prevention and compliance [7] Group 3: Tax Benefits and Support - Zhuzhou Dibao Optoelectronic Materials Co., Ltd. has benefited significantly from tax policies, receiving over 47 million yuan in VAT reductions and more than 2.6 million yuan in corporate income tax exemptions [5] - The tax authority's guidance has enabled companies to efficiently enjoy tax benefits, enhancing their operational capabilities [5] Group 4: Credit and Development - Companies with high tax credit ratings, such as Zhuzhou Yinuo Biotechnology Co., Ltd., have experienced improved efficiency in expanding overseas markets [8] - The local tax authority aims to enhance the credit ratings of over 120 enterprises in 2024, converting tax credit into financing credit to support business growth [9]

Core Viewpoint - Shah Capital, the second-largest shareholder of Novavax, is urging the biotechnology company to make strategic adjustments, including a potential sale, due to dissatisfaction with the weak sales of its COVID-19 vaccine [1] Group 1: Shareholder Actions - Shah Capital has increased its stake in Novavax from 7.2% in October to approximately 8.3% [1] - The shareholder has warned that if there is no progress within the next four months, it may initiate a proxy fight [1]

Group 1: Tuda Technology's IPO Progress - Tuda Technology has passed the Hong Kong Stock Exchange hearing, indicating readiness for public listing [1] - The company delivered approximately 181,000 automotive-grade LiDAR units in the first nine months of 2025, representing a year-on-year growth of 7.7% [1] - Tuda Technology achieved positive gross profit for four consecutive quarters from Q4 2024 to Q3 2025, with cumulative deliveries of its main LiDAR product "Falcon" exceeding 600,000 units [1] Group 2: Anker Innovations' IPO Announcement - Anker Innovations announced plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [2] - The company aims to consider the interests of existing shareholders and market conditions to choose an appropriate timing for the issuance [2] - This move is part of Anker's strategy to establish an "A+H" platform, enhancing international financing channels and global brand recognition [2] Group 3: Axbio International's Listing Application - Axbio International has submitted a listing application to the Hong Kong Stock Exchange, with joint sponsors being CICC and PSBC International [3] - The company specializes in molecular diagnostic instruments and biochips, holding a leading position in this field since its establishment in 2016 [3] - Axbio's product portfolio includes a microarray chip analyzer, two EL-NGS gene sequencers, and various testing kits, all developed in-house [3] Group 4: Copper Master’s Listing Application - Copper Master has submitted a listing application to the Hong Kong Stock Exchange, with CMB International as the exclusive sponsor [4] - The company focuses on integrating traditional craftsmanship with modern design, developing copper cultural products [4] - As of the end of 2024, Copper Master is projected to hold a 35.0% market share in China's copper cultural craft product market, ranking first by total revenue [4]

Summary of Bright Minds Biosciences FY Conference Call Company Overview - **Company**: Bright Minds Biosciences (NasdaqCM:DRUG) - **Focus**: Development of therapies targeting serotonin receptors, specifically the 5-HT2 family - **Current Clinical Assets**: - BMB-101 in Phase 2 for two types of epilepsy: developmental and epileptic encephalopathies (DEEs) and absence epilepsy - New program targeting Prader-Willi syndrome (PWS) with a 5-HT2C molecule - Several preclinical assets focusing on the 5-HT2A receptor for potential use in pain and neuropsychiatric disorders [2][60] Key Points and Arguments Clinical Development - **BMB-101**: - A G protein-based agonist at the 5-HT2C receptor, differentiating it from other compounds like fenfluramine and BMB-101 by avoiding beta-arrestin pathway activation, which can lead to tolerance [3][4] - Better pharmacokinetics (PK) with a proposed once-daily formulation compared to BMB-101, which requires refrigeration and is taken three times a day [4][7] - Phase 1 data indicates better tolerability and a linear dosing response, reducing side effects compared to BMB-101 [8][9] Epilepsy Indications - **Absence Epilepsy**: - The FDA is interested in absence seizures due to the lack of effective treatments; EEG is a reliable measurement tool for these seizures [16][17] - The benchmark for approval is a 50% reduction in seizures in 50% of patients, adjusted for placebo effects [17][18] - Enrollment target for the study is about 10 patients, with doses ranging from 0.67 to 2 mg/kg [28][31] - **Developmental and Epileptic Encephalopathies (DEEs)**: - Majority of patients will likely be from the Lennox-Gastaut syndrome (LGS) population, with a similar benchmark for efficacy as absence epilepsy [36][38] - Multi-center trial being conducted in Australia, with plans for a global Phase 2/3 trial [37][44] Market Opportunity - **DEEs**: Potential peak sales for treatments in this area are estimated at $1.5 billion to $2 billion [49] - **Absence Epilepsy**: Bright Minds aims to be the first branded agent in this indication, with a patient population estimated at around 275,000 to 500,000 annually [49][51] Prader-Willi Syndrome (PWS) - **Mechanistic Rationale**: Genetic link to 5-HT2C receptors in PWS patients; targeting these receptors may alleviate symptoms including hyperphagia and neuropsychiatric issues [60] - **Clinical Evidence**: Previous studies with fenfluramine showed improvements in weight and neuropsychiatric symptoms, supporting the rationale for 5-HT2C agonism in PWS [60] Financials and Capitalization - The company is operating with a focus on capital efficiency, with current funding covering ongoing and upcoming studies [69] Additional Important Information - Future studies planned for both DEE and absence epilepsy, with a need for regulatory alignment on seizure counting methods [46][48] - The company is also advancing a second asset, BMB-105, to potentially save time in development [62][63] - The upcoming data release is expected in early January, strategically timed to capture investor attention [42]

Financial Data and Key Metrics Changes - As of September 30, 2025, the company had cash, cash equivalents, restricted cash, and short-term investments totaling $207.5 million, providing significant financial flexibility for the ZEVASKYN commercial launch [15] - Research and development (R&D) spending for Q3 2025 was $4.2 million, a decrease from $8.9 million in Q3 2024, primarily due to costs capitalized into inventory and reclassification of certain costs to selling, general, and administrative expenses (SG&A) [16] - SG&A expenses increased to $19.3 million in Q3 2025 from $6.4 million in Q3 2024, reflecting the reclassification of R&D expenses and increased costs associated with the commercial launch [16] - The net loss for Q3 2025 was $5.2 million, or -$0.10 per share, compared to a net loss of $30.3 million, or -$0.63 per share, in Q3 2024 [16] Business Line Data and Key Metrics Changes - The ZEVASKYN commercial launch is progressing, with growing patient demand and the activation of a third qualified treatment center (QTC), Children's Hospital Colorado [5][12] - The number of identified eligible patients at QTCs has more than doubled to approximately 30, up from over 12 previously reported [11] - The company has received ZEVASKYN Product Order Forms (ZPOFs) for 12 patients, indicating strong interest and movement towards treatment [10] Market Data and Key Metrics Changes - ZEVASKYN has received coverage decisions from all major commercial payers, covering over 80% of commercially insured lives, and has baseline coverage across all 51 state Medicaid programs [13] - A permanent product J-code for ZEVASKYN will be established by CMS effective January 1, 2026, which is expected to simplify claims and reimbursement processing [14] Company Strategy and Development Direction - The company is focused on scaling the ZEVASKYN commercial launch to meet patient demand and expanding its QTC network [5] - The management is actively discussing the onboarding of additional EB centers across the U.S. to further expand ZEVASKYN's geographic footprint [12] - The company aims to achieve profitability in the first half of 2026, despite the delay in the first patient treatment [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2026 launch goals based on trends in patient demand and market access, despite a temporary delay in the first patient treatment [5][6] - The management highlighted the importance of maintaining high-quality standards in manufacturing personalized drug products [8] - The company is encouraged by the doubling of identified patients and the favorable payer landscape for ZEVASKYN [19] Other Important Information - The company has paused collecting additional patient biopsies to investigate and optimize a release assay that encountered performance issues [9] - The gene therapy program for X-linked retinoschisis, ABO-503, has been selected for the FDA Rare Disease Endpoint Advancement Pilot Program, which may accelerate development [18] Q&A Session Summary Question: Expected timeline for patients to receive treatment - Management indicated that several patients have already been scheduled for biopsy in November and early 2026, with treatment expected to follow if all paperwork is completed [24][26] Question: Impact on profitability timeline due to treatment delays - Management does not foresee a significant impact on the timeline for achieving profitability, maintaining guidance for the first half of 2026 [30] Question: Status of routine maintenance shutdown - The company confirmed a planned shutdown for routine maintenance starting mid-December and lasting about a month [34][35] Question: Biopsy collection during optimization pause - No biopsies were collected during the pause; the company prioritized resolving the assay issue before proceeding [36] Question: Lead time for ZEVASKYN Product Order Forms - Management expects the lead time to decrease as more patients progress through the treatment process and payer policies become established [39][42] Question: Attrition rate among patients with ZPOFs - Management anticipates a high conversion rate for patients with ZPOFs, as these are motivated patients who have expressed interest in treatment [47][49] Question: Prior authorization process for RDEB patients - The prior authorization process involves clinical and financial discussions, with most payers following inclusion/exclusion criteria from clinical trials [52] Question: Revenue recognition timeline - Revenue is recognized when the product is administered to the patient, with cash flow considerations varying by site [58]

Core Insights - Jiangyin WuXi AppTec Co., Ltd. has recently established Jiangyin WuXi HeLian Biotechnology Co., Ltd. with a registered capital of 215 million yuan [1] Company Information - The legal representative of the newly established company is Jincai Li [1] - The business scope includes drug production, drug import and export, entrusted drug production, domestic trade agency, offshore trade operations, import and export commodity inspection and appraisal, chemical product sales, general cargo warehousing services, and cargo packing services [1] - The company is wholly owned by Wuxi WuXi HeLian Biotechnology Co., Ltd. [1]